Analysts Anticipate Avid Bioservices Inc (NASDAQ:CDMO) Will Post Earnings of -$0.04 Per Share

Share on StockTwits

Wall Street brokerages expect that Avid Bioservices Inc (NASDAQ:CDMO) will report earnings per share (EPS) of ($0.04) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Avid Bioservices’ earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.02). Avid Bioservices reported earnings per share of ($0.06) in the same quarter last year, which indicates a positive year over year growth rate of 33.3%. The company is expected to announce its next earnings results after the market closes on Monday, December 9th.

According to Zacks, analysts expect that Avid Bioservices will report full-year earnings of ($0.18) per share for the current financial year, with EPS estimates ranging from ($0.28) to ($0.09). For the next fiscal year, analysts expect that the business will post earnings of $0.06 per share, with EPS estimates ranging from ($0.01) to $0.20. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Avid Bioservices.

Avid Bioservices (NASDAQ:CDMO) last posted its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.05). Avid Bioservices had a negative net margin of 9.63% and a negative return on equity of 11.89%. The business had revenue of $15.25 million during the quarter, compared to analyst estimates of $14.37 million. The company’s revenue was up 21.1% compared to the same quarter last year.

Several equities analysts recently weighed in on the stock. Craig Hallum assumed coverage on shares of Avid Bioservices in a research note on Wednesday, October 16th. They issued a “buy” rating and a $11.00 target price for the company. ValuEngine cut shares of Avid Bioservices from a “buy” rating to a “hold” rating in a research note on Thursday, September 26th. TheStreet cut shares of Avid Bioservices from a “c-” rating to a “d+” rating in a research note on Thursday, September 12th. Zacks Investment Research raised shares of Avid Bioservices from a “sell” rating to a “hold” rating in a research note on Tuesday, November 12th. Finally, HC Wainwright set a $11.00 target price on shares of Avid Bioservices and gave the company a “buy” rating in a research note on Friday, September 6th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $8.95.

In related news, major shareholder Joseph Carleone acquired 15,247 shares of Avid Bioservices stock in a transaction on Monday, September 9th. The stock was purchased at an average cost of $9.20 per share, with a total value of $140,272.40. Also, CEO Richard B. Hancock acquired 10,000 shares of Avid Bioservices stock in a transaction on Tuesday, September 10th. The shares were bought at an average cost of $5.09 per share, with a total value of $50,900.00. 1.20% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in CDMO. Millennium Management LLC boosted its position in Avid Bioservices by 3,584.8% during the third quarter. Millennium Management LLC now owns 827,284 shares of the biopharmaceutical company’s stock worth $4,384,000 after purchasing an additional 804,833 shares during the period. AWM Investment Company Inc. bought a new position in Avid Bioservices during the second quarter worth $3,952,000. River & Mercantile Asset Management LLP bought a new position in Avid Bioservices during the second quarter worth $2,674,000. BlackRock Inc. boosted its position in Avid Bioservices by 7.5% during the second quarter. BlackRock Inc. now owns 3,790,286 shares of the biopharmaceutical company’s stock worth $21,227,000 after purchasing an additional 266,015 shares during the period. Finally, AltraVue Capital LLC boosted its position in Avid Bioservices by 6.7% during the second quarter. AltraVue Capital LLC now owns 2,108,812 shares of the biopharmaceutical company’s stock worth $11,810,000 after purchasing an additional 133,337 shares during the period. 45.05% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:CDMO traded up $0.12 during midday trading on Wednesday, hitting $5.76. The stock had a trading volume of 327,075 shares, compared to its average volume of 302,851. Avid Bioservices has a 12 month low of $3.37 and a 12 month high of $7.15. The company has a quick ratio of 1.50, a current ratio of 1.78 and a debt-to-equity ratio of 0.47. The business’s 50-day simple moving average is $5.28 and its 200-day simple moving average is $5.40. The company has a market cap of $323.93 million, a P/E ratio of -33.88 and a beta of 2.70.

About Avid Bioservices

Avid Bioservices, Inc, a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

See Also: What is a good dividend yield?

Get a free copy of the Zacks research report on Avid Bioservices (CDMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avid Bioservices (NASDAQ:CDMO)

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.